SMARCA1 and rhabdoid tumor: Similarly, in malignant rhabdoid tumours, SMARCB1 loss reduces the ability to bind to typical enhancers, but not to super-enhancer sites, indicating that the residual SWI/SNF subunits are sufficient for tumour progression and survival through formation of ncBAF complexes [21, 23].